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Jeffrey D. Crawford, MD, Kenneth H. Perrone, BS, Victor W. Wong, MD, Erica L. Mitchell, MD,
Amir F. Azarbal, MD, Timothy K. Liem, MD, Gregory J. Landry, MD, and Gregory L. Moneta, MD,
Portland, Ore
Objective: Acute aortic occlusion (AAO) is a rare condition associated with substantial morbidity and mortality. The most
recent large series was published over 15 years ago and included patients from the 1980s. Previous studies reported up to
50% of AAOs are caused by embolization, with a mortality rate approaching 50%. We reviewed our recent experience with
AAOs to identify current etiologies and outcomes in a contemporary series of patients with AAOs.
Methods: Current Procedural Terminology codes and data from a prospectively maintained vascular surgical database were
used to identify patients with acute occlusion of the native aorta between 2005 and July 2013. AAOs secondary to
trauma, dissection, or graft occlusion were excluded.
Results: We identiﬁed 29 patients with AAOs treated at our institution. Twenty-three patients were transferred from
referring hospitals with a mean transfer time of 3.9 hours (range, 0.5-7.5 hours). Twenty-two presented with occlusion
below the renal arteries and seven with occlusion extending above the renal arteries. Resting motor/sensory lower
extremity deﬁcits were noted in 17 patients. Eight patients presented with complete paraplegia. Etiology was felt to be
aortoiliac thrombosis in 22 cases, embolic occlusion in 2, and indeterminate in 5. Surgical revascularization was per-
formed in 26 cases (extra-anatomic bypass in 18, thromboembolectomy in 5, and aortobifemoral bypass in 3 patients.
Three patients had no intervention. Acute renal failure developed in 15 patients and rhabomyolysis in 10 patients.
Fasciotomy was performed in 19 extremities. Nine extremities were amputated in six patients. Overall mortality was 34%
with a 30-day mortality of 24% and a postprocedure mortality of 15%.
Conclusions: AAO is an infrequent but devastating event. The dominant etiology of AAOs is now thrombotic occlusion.
Despite advances in vascular surgery and critical care over the past 2 decades, associated morbidity and mortality remain
substantial with high rates of limb loss, acute renal failure, rhabdomyolysis, and death. Mortality may be improved with
expeditious extra-anatomic bypass. (J Vasc Surg 2014;59:1044-50.)Acute aortic occlusion (AAO) is an uncommon but
potentially devastating event that requires prompt diag-
nosis and emergent intervention. Previous reports indicate
mortality rates ranging from 25% to 75%.1-6 AAOs can
result from a large saddle embolus to the aortic bifurcation,
in situ thrombosis of an atherosclerotic aorta, or acute
occlusion of an abdominal aortic aneurysm. The clinical
presentation is sudden and characterized by lower
extremity pain, paralysis, and mottled extremities. The
diagnosis can occasionally be mistaken for stroke or
a central nervous system lesion.5,7 A delay in diagnosis
prolongs time to appropriate intervention with resultant
increased morbidity and mortality. Ischemic complications
including gastrointestinal malperfusion, renal infarction,
and paralysis secondary to spinal cord ischemia can occur.the Division of Vascular Surgery, Department of Surgery, Knight
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4The current understanding of AAOs is largely based on
case series and reports from several decades ago. In this
study, we review our recent institutional experience with
AAOs to re-evaluate putative mechanisms and current
outcomes in a modern series of patients with AAOs.METHODS
The study was approved by the Institutional Review
Board of Oregon Health and Science University. This
was a retrospective review of a prospective vascular surgical
database and electronic medical records. Current Proce-
dural Terminology codes 34151, 34201, 35521, 35533,
35540, 35621, 35646, 35654 were used to identify
patients, and the electronic medical record was cross-
referenced to conﬁrm all patients had acute occlusion of
the native aorta from 2005 to July 2013. AAOs secondary
to trauma, aortic dissection, or graft occlusion were
excluded. Of note, during the study period, there were
no acute total endograft occlusions identiﬁed. We identi-
ﬁed one patient with an AAO of an aortic graft several years
following elective open abdominal aortic aneurysm repair.
This patient is not included in the analysis.
Information regarding demographic, operative and
postoperative characteristics, amputation, and fasciotomy
occurrence were collected from the electronic medical
records. Rhabdomyolysis was deﬁned by creatine kinase
(CK) levels >10,000 U/L, as this was also our institutional
threshold to treat with forced alkaline diuresis according to
the protocol built by Malinoski et al.8 Acute renal failure
Table I. Patient characteristics
No. (%) (N ¼ 29)
Median age at diagnosis 6 SD, years 60.7 6 13.8
Male 17 (59)
PAD 16 (55)
Arrhythmia 5 (17)
Valvular heart disease 4 (14)
CHF 6 (21)
CAD 13 (45)
CVA/TIA 5 (17)
HTN 20 (69)
HLD 12 (41)
CRI 5 (17)
Diabetes 8 (28)
Tobacco 22 (76)
Thrombophilia 5 (17)
Cancer 7 (24)
CAD, Coronary artery disease; CHF, congestive heart failure; CRI, chronic
renal insufﬁciency; CVA/TIA, cerebrovascular accident/transient ischemic
attack; HLD, hyperlipidemia; HTN, hypertension; PAD, peripheral artery
disease; SD, standard deviation.
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serum creatinine of >50% within 48 hours. Tobacco use
was deﬁned as any prior history of smoking or current
smoker. Congestive heart failure, coronary artery disease,
arrhythmia, valvular heart disease, peripheral artery disease,
cerebrovascular accident/transient ischemic attack, and
chronic renal insufﬁciency were considered present if docu-
mented in the electronic medical record. Hyperlipidemia,
diabetes, and hypertension were determined by documen-
tation in the electronic medical record or by documented
use of medications to treat these conditions. Thrombo-
philia was deﬁned by a panel of coagulation studies as inter-
preted and deﬁned by our hematology colleagues.
Transport time was determined by the time from the
ﬁrst documented communication of the referring center
to our institution to the time of arrival of the patient to
our facility. Time to operation was deﬁned by patient or
family-reported time of symptom onset to the operating
room. Follow-up was determined by date of last follow-
up at our institution. The Social Security Death Index
was employed to determine long-term mortality. Level of
aortic occlusion was determined from preoperative imaging
studies (computed tomography [CT], CT angiography
[CTA], ultrasound, or angiography). History, physical
examination ﬁndings, imaging studies, transthoracic/trans-
esophageal echocardiography, and operative ﬁndings were
used to classify the etiology of AAOs as thrombotic or
embolic. c2 analysis was used to calculate the P value of
categorical data to compare time to revascularization and
transfer patients to 30-day mortality and need for amputa-
tion. A P value <.05 was considered signiﬁcant. All statis-
tical analyses were computed using SPSS Statistics v21
(IBM Corp, Armonk, NY).
RESULTS
There were 29 patients with AAOs (Table I). The level
of occlusion was infrarenal (below the renal arteries) in 22
patients and isolated to the aortic bifurcation (below the
inferior mesenteric artery [IMA]) in six. Occlusion
extended above the renal arteries but below the superior
mesenteric artery (SMA) in ﬁve and above the SMA in
two patients (Fig 1). Level of occlusion was determined
by preoperative imaging including CT/CTA in 23 cases,
angiogram in 3, and duplex ultrasound in 3 cases. Twelve
patients had bilateral internal iliac artery occlusion, ﬁve
patients had unilateral internal iliac artery occlusion, and
seven had patent internal iliacs bilaterally. Patency could
not be assessed in ﬁve patients. All occlusions involved at
least the bilateral common iliac arteries. Based on imaging
studies, patient history, and operative ﬁndings, aortoiliac
thrombosis was felt to account for 22 of the AAO cases
(76%) and embolic occlusion in two (7%) cases (Fig 2).
In ﬁve cases, etiology of the AAO was indeterminate
(17%). Both patients with embolic aortic occlusion were
found to have a left ventricular thrombus on transthoracic
echocardiography; one had a history of atrial ﬁbrillation but
was not on anticoagulation. Thrombophilia work-up was
selectively performed at surgeon discretion and primarilyin younger patients. Thrombophilia was diagnosed after
presentation in ﬁve patients. The mean age of patients
with thrombophilia was 45.2 years (range, 24-66 years).
All ﬁve were diagnosed with antiphospholipid antibody
syndrome. Seven patients had a known malignancy,
including active and inactive bladder cancer (2), active
lung cancer (2), active metastatic colon and renal cell
cancer (1), active lymphoma (1), and active metastatic
melanoma (1), thus indicating that over 40% of patients
had an identiﬁed potential hypercoagulable state. There
was no signiﬁcant difference in the pattern of thrombosis
in these 12 patients with a hypercoagulable state. Ten of
these patients had an AAO below the renal arteries, and
two patients had renal artery involvement.
Twenty-three patients presented as a transfer from
a referring institution. Mean transport time was 3.9 hours
(range, 0.5-7.5 hours). Lower extremity motor/sensory
deﬁcits were present on admission in 17 patients, and eight
patients had complete paraplegia. Time from patient or
family-reported symptom onset to the operating room
was <24 hours in 16 patients, >24 hours in 12 patients,
and unknown in one patient. Median time from initiation
of transfer and start time of operation was 13.8 hours
(range, 4.0-192.0 hours). Extra-anatomic bypass was per-
formed in 18 patients, thromboembolectomy in 5, and aor-
tobifemoral bypass in 3 (Fig 3). Three patients had no
intervention. No patients were treated with thrombolytic
therapy. Median length of initial procedures including
adjuncts of fasciotomy or amputation was 5.3 hours (range,
2.0-11.3 hours).
Overall mortality was 34% with a 30-day mortality rate
of 24%. Excluding patients who did not undergo surgery,
postprocedure 30-day mortality was 15%. Overall and 30-
day mortality of infrarenal AAOs (infrarenal and bifurca-
tion, n ¼ 22) was 32% and 18%, respectively. Suprarenal
AAOs (renal and SMA, n ¼ 5) was associated with an over-
all and 30-day mortality rate of 42%. Overall mortality for
Fig 1. Level of aortic occlusion. The gray represents the segment of abdominal aorta occluded by thrombus or
embolus diagnosed by computed tomography angiography (CTA), duplex ultrasound, or angiography. Internal iliac
arteries were occluded bilaterally in 12 patients, unilateral occlusion present in 5, and patent in 7 patients. Patency could
not be assessed in ﬁve patients. SMA, Superior mesenteric artery. Original ﬁgure created by Victor W. Wong.
Fig 2. Etiology of acute aortic occlusions (AAOs). Fig 3. Revascularization. A total of 26 patients underwent revas-
cularization with the number of patients given in parentheses.
Three patients had no intervention.
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plegia was 28% and 24%, respectively. Patients with a hyper-
coagulable state from antiphosphlipid antibody syndrome
(n ¼ 5) and a known malignancy (n ¼ 7) had an overall
mortality of 42% compared with 29% in patients without
a known hypercoagulable state. Eight deaths occurred
postoperatively during the initial hospitalization, one of
which occurred greater than 30 days postoperatively.
Causes of death included sepsis/multiorgan failure (5),
myocardial infarction (2), stroke (1) and unknown (2).Mean follow-up for all patients was 10.8 months (range,
0.01-102.2 months).
There was no signiﬁcant difference in 30-day mortality
or time from symptom onset to revascularization between
patients who were transferred and those brought directly
to our institution (P ¼ .22 and P ¼ .52, respectively).
Preoperative history of hypertension and ARF were associ-
ated with statistically signiﬁcant increased risk of 30-day
JOURNAL OF VASCULAR SURGERY
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tobacco use, motorsensory deﬁcit on presentation, and
AAO at the renal arteries were associated with worse 30-
day mortality but did not reach statistical signiﬁcance. A
history of claudication was protective and associated with
improved 30-day survival (not statistically signiﬁcant
[NS]).
A total of nine limbs were amputated in six patients.
Four limb amputations were performed after the initial
operation, but none was a result of graft failure or occlu-
sion. Bilateral above-knee amputation was performed for
three patients. There was no correlation between transfer
patients or time to revascularization of >24 hours and
need for amputation (P ¼ .74 and P ¼ .16, respectively).
Tobacco use, chronic renal insufﬁciency, motorsensory
deﬁcit on presentation, and AAO at the renal arteries
were associated with need for amputation but did not reach
statistical signiﬁcance. Amputation was required in 69% of
patients without a history of claudication and only 30% of
claudicants (NS). Fasciotomies were performed in 19
limbs, and all were done at the time of initial surgery.
Subsequent debridement of fasciotomy sites was required
in four patients.
There was one graft occlusion within 30 days of revas-
cularization that was treated with thrombectomy of the
occluded axillofemoral graft. It occurred in a patient anti-
coagulated on fondaparinux for heparin-induced throm-
bocytopenia. One patient required thrombectomy of
a thrombosed axillobifemoral graft 7 months following
initial revascularization, and another was found to have
graft occlusion 7 years following the initial procedure.
One patient required ligation of a right axillobifemoral
graft and exchange for a left axillary bifemoral graft for
worsening claudication and right subclavian artery stenosis
6 months following the initial revascularization.
Other complications included ARF (n ¼ 15; 52%),
need for hemodialysis (HD; n ¼ 4; 14%), rhabdomyolysis
(n ¼ 10; 34%), sustained motorsensory neurologic deﬁcit
(n ¼ 8; 28%), myocardial infarction (n ¼ 4; 14%), mesen-
teric ischemia (n ¼ 4; 14%), and need for reoperation (n ¼
14; 48%). The range of CK was 10,593 to 95,981 U/L.
with a median CK level of 45,108 U/L in patients with
rhabdomyolysis. Treatment of rhabdomyolysis was guided
by an institutional protocol focusing on crystalloid resusci-
tation to maintain high urine output, alkalinization of
urine, hyperosmolar diuresis, and HD if required. Reoper-
ations included late amputation (4), debridement, closure,
or skin grafting of fasciotomy sites (4), exploratory lapa-
rotomy (3), and revascularization (4). Redo revasculariza-
tion procedures included femoral-popliteal bypass (1),
thrombectomy (2), and redo extra-anatomic bypass (1).
Five patients had renal artery involvement (Fig 1). One
was treated with thrombectomy and left nephrectomy for
renal infarction and necrosis. This patient developed ARF
but did not require HD and survived. Two patients were
treated with axillobifemoral bypass and aggressive anticoa-
gulation. One patient survived and never developed
ARF or needed HD. The other patient undergoingaxillobifemoral bypass developed ARF and died on postop-
erative day 3 from a massive myocardial infarction prior to
initiation of HD. Two patients were critically ill and transi-
tioned to palliative care and died without an intervention.
Both surviving patients with renal artery involvement pre-
sented early with transport times less than 2 hours and
were taken immediately to the operating room.
Both patients with aortic occlusion above the SMA
developed mesenteric ischemia. They both survived and
are still living. Both were treated with aortobifemoral
bypass with grafts to visceral arteries (supraceliac aorta to
common hepatic artery and end-to-side aortic graft to
IMA in one patient and left limb of aortic graft to SMA
in the other). Of the six patients with AAO of the bifurca-
tion, only one patient was successfully treated with throm-
boembolectomy alone.
Two patients with infrarenal AAO developed colonic
mesenteric ischemia postoperatively, and neither survived.
One died of sepsis and multiorgan failure following
aortoembolectomy and embolectomy of the IMA. The
other developed signiﬁcant rectal bleeding with hemody-
namic compromise several days following aortobifemoral
bypass and was transitioned to comfort care. Therapeutic
anticoagulation with warfarin, enoxaparin, or fondaparinux
was continued at discharge in 57% of patients. All patients
were discharged on aspirin or clopidogrel.
DISCUSSION
AAO is infrequent. However, the diagnosis should not
be difﬁcult. The sudden onset of bilateral leg pain, neuro-
logic deﬁcits, and lower extremity mottling should alert the
physician to AAO. A careful pulse exam coupled with CTA
distinguishes neurologic from vascular causes and should
expedite subsequent treatment (Fig 4). However, despite
the obvious diagnosis at presentation in most cases,
outcomes for patients with AAOs continue to be marked
with signiﬁcant morbidity and mortality.
This modern series of AAOs is one of the largest series
reported and was collected over the shortest study period.
It is the only large series to be published in 15 years. Our
recent 7-year experience with 29 patients indicates that the
etiology of AAOs has shifted to primarily thrombotic rather
than embolic. Dossa et al reported a 40-year experience of
AAOs from 1953 to 1993 in which 46 patients were iden-
tiﬁed. In this analysis, 65% of cases were embolic and 35%
thrombotic; however, the frequency of thrombotic AAO
increased with each decade.6 Surowiec et al, in their study
of 33 patients from 1985 to 1997, showed 52% of AAOs to
be thrombotic and 48% embolic (Table II).7 Our study is
therefore consistent with previous studies demonstrating
an evolving etiology and that the majority of AAOs are
now thrombotic in nature. This may reﬂect a population
with advanced aortoiliac atherosclerosis; however, the
comorbidities of our patient population are similar to those
reported in other studies (Table II). This change may also
be a result of improved prevention of cardioembolic events
with anticoagulation for patients with atrial ﬁbrillation
and/or valvular heart disease. Lastly, hypercoagulability is
Fig 4. Sagittal computed tomography angiography (CTA) demonstrating acute aortic occlusion (AAO) of the
infrarenal aorta (left). Sagittal CTA of a patient with an AAO above the superior mesenteric artery (SMA) with a patent
celiac artery and distal reconstitution of the SMA (right).
Table II. Comparison of acute aortic occlusion (AAO) series
Author
Year
Crawford
2013
Suroweic7
1998
Babu9
1995
Dossa6
1994
Bradbury10
1993
Webb5
1986
Litooy4
1986
Danto2
1974
No. of patients 29 33 48 46 14 10 18 9
Study duration, years 7 12 19 40 8 10 9 9
Age, years 61 65 35-85 59 66 62 61 58
Male 59 52 46 41 71 90 78 55
PAD 55 70 82 - 79 40 - 78
Arrhythmia 17 33 - - 14 - - 22
CHF 21 21 - - - - - 44
CAD 45 67 58 74 - 70 72 33
HTN 69 - 60 48 - - - -
Tobacco use 76 33 - 33 93 60 - -
DM 28 18 - 26 0 40 - 11
Presentation and etiology
Thrombosis 76 52 92 35 50 - 44 0
Embolus 7 48 8 65 50 - 56 100
Motorsensory deﬁcit 59 33 17 83 71 90 78 100
Morbidity and mortality
ARF/HD 52/14 15/- - 24/4 50/29 20/- 61/28 44/-
Rhabdomyolysis 34 - - 26 - - - -
Amputation, No. of limbs 16 12 31a 9 7 10 11 6
Fasciotomy, No. of limbs 33 - 20a - 50/29 - 50a -
Motorsensory deﬁcit 28 - 0 11 29 - 6 -
Mesenteric ischemia 14 6 10 9 14 - - -
MI 14 9 - 13 - - 17 -
30-day mortality, No. (%) 24 (15)b 21 52 31 38 50 50 22
ARF, Acute renal failure; CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; HD, hemodialysis; HTN, hypertension; MI,
myocardial infarction; PAD, peripheral artery disease.
All numbers represent a percentage (%) unless otherwise noted. Dash mark (-) indicates the data were not reported in the publication.
aNot speciﬁed in original article if this number represents number of extremities or number of patients.
bPostprocedure mortality.
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a hypercoagulable state from either antiphospholipid anti-
body syndrome (17%) or malignancy (24%).
A shifting etiology of AAOs has implications for the
care of patients with AAOs. First, the postproceduremortality in our study is signiﬁcantly reduced compared
with other studies. This may be a result of improved critical
care or perhaps related to the high number of thrombotic
occlusions in our series. Such patients may have had the
advantage of forming collaterals, which may improve their
Table III. Operative approach for acute aortic occlusion (AAO)
Author
Year
Crawford
2013
Suroweic7
1998
Babu8
1995
Dossa6
1994
Bradbury9
1993
Webb5
1986
Litooy4
1986
Danto2
1974
No. of patients 29 33 48 46 14 10 18 9
Ax-bifem 18 5 12 5 1 2 0 0
Thromboembolectomy 5 15 11 28 0 3 14 1
Aorto-bifem 3 9 22 9 12 4 4 8
Aorto-bifem, Aortobifemoral bypass; Ax-bifem, axillobifemoral bypass.
All values represent number (n) of cases reported in series (not a percentage).
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most of our patients presented to rural community hospi-
tals where appropriate surgical expertise may not be as
readily available to deal with the complex revascularization
procedures and the intensive postoperative care required. It
is our feeling that, if the obvious cause of the AAO is
embolic, the patient is best served with surgical embolec-
tomy at his or her local hospital followed by transfer for
the complex postoperative care often required. However
if thrombotic occlusion is suspected, even in the face of
signiﬁcant ischemia, the patient should be expeditiously
transferred and cared for by a surgeon and an institution
experienced in the complex vascular techniques and post-
operative care required to re-establish lower extremity
perfusion in such cases.
Compared with other series of AAOs, a higher propor-
tion of our patients was treated with axillobifemoral bypass
(Table III). Aortic-based operations were only performed
in selected cases where the thrombosis extended above
the renal arteries, and the circumstances were felt necessary
for an aortic-based reconstruction. Our choice of axillobife-
moral bypass for emergent revascularizations reﬂects our
familiarity with this procedure, excellent short-term
patency of this reconstruction in these difﬁcult patients,
and the belief that the physiologic impact is less compared
to aortobifemoral bypass under the circumstances of
AAO.11 It also reﬂects the fact that most of our patients
were not amenable to simple embolectomy.
None of our patients was treated with thrombolytic
therapy or catheter-based interventions, although those
without signiﬁcant motor deﬁcits and occlusion limited
to the distal abdominal aorta may be potential candidates.
It is, however, our belief that the large majority of patients
currently presenting with AAOs are most efﬁciently and
safely treated with prompt open extra-anatomic revascular-
ization with concurrent adjunctive procedures such as
amputation or fasciotomy if necessary. Furthermore,
despite the patients being severely ill and the potential for
reperfusion-related systemic complications, mortality in
patients undergoing extra-anatomic bypass does not appear
to be directly related to the surgical procedure. In fact, our
postprocedure mortality appears improved compared with
earlier series (Table III). Finally, rhabdomyolysis is
a frequent complication in AAO patients, and the use of
additional contrast associated with catheter-based tech-
niques of revascularization may place the patient at in-
creased risk of further renal insufﬁciency.Our general algorithm for diagnosis and management
of these patients is to perform CTA to conﬁrm the diag-
nosis. Palliative care consultation is considered in patients
with severe debilitating comorbidities, end-stage malignan-
cies, or severe extremis. Appropriate patients for revascular-
ization are then heparinized and taken emergently to the
operating room where femoral artery cutdowns are per-
formed and attempts made at thromboembolectomy. If
adequate inﬂow cannot be reestablished or ﬁndings on
CTA demonstrate a signiﬁcant clot burden, then extra-
anatomic bypass is performed. Patients with an AAO above
the renal arteries are treated with aortic-based reconstruc-
tion with aortobifemoral bypass with branched grafts to
visceral arteries as needed.
CONCLUSIONS
AAO remains associated with high morbidity; however,
mortality may be curtailed by expeditious extra-anatomic
bypass. The etiology of AAOs has evolved and is now
primarily thrombosis of the abdominal aorta rather than
embolism. Prompt recognition of AAOs and appropriate
transfer for surgical intervention are paramount to
improving outcomes. Axillobifemoral bypass, when
feasible, is preferred for most patients with AAOs as it
provides efﬁcient revascularization with minimal physio-
logic impact.
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263-71.Submitted Aug 19, 2013; accepted Oct 16, 2013.DISCUSSIONDr Mark Morasch (Billings, Mont). First, I would like to
offer my congratulations to Dr Crawford and his colleagues on
an excellent presentation, a strong manuscript, and for being
considered for the “best trainee paper” award. The group from
Oregon Health Sciences University has presented a retrospective
review of a reasonably contemporary series of patients who pre-
sented to their institution with acute aortic occlusion. While similar
case-series have been published before, this is the ﬁrst to be pre-
sented this century. Perhaps the most notable conclusion is that
despite obvious advances in the care and treatment of the surgical
patient, over the last 35 years, we have been unable to bend the
mortality curve for this acute catastrophe. The overall mortality
of 34% in this paper is similar to the 50% published by my mentors,
Littooy and Baker, in 1986, the 31% published by the group from
Vanderbilt in 1992, 35% from Alex Shepard at Henry Ford in
1994, and 21% from Alan Lumsden when he was at Emory in
1998. This is also despite another consistent ﬁnding, that these
patients, at least by vascular surgery standards, are relatively young.
In fact, they average not much more than 60 years of age in this
and all the prior studies. Part of me wants to conclude that in
a third of patients, the die is cast at the time of the occlusion
and there is nothing the surgeon can do to preserve life; despite
our best efforts, the curve simply cannot be bent. The other part
wants to believe that we can do better with this entity. Maybe
earlier treatment could help. Perhaps some technical adaptation,
like more aggressively approaching the aorta directly, might save
lives. Could more frequent postoperative imaging to assure we
have left no residual clot make a difference?
My questions for Dr Crawford may be more philosophical or
rhetorical than technical, but do the authors have any ideas,
based on their experience, what we might do to effect outcomes?
Or, if they feel that there is nothing that can be done, might
there be a subgroup of patients who could be identiﬁed up front
that should be offered comfort care only? I appreciate the oppor-
tunity to comment on this paper and look forward to your
response.Dr Jeffrey D. Crawford. Dr Morasch, thank you for review-
ing this manuscript and for your insights and questions. You are
correct in that acute aortic occlusion (AAO) continues to be asso-
ciated with signiﬁcant morbidity and mortality. However, we
believe that our series with a postprocedure mortality of 15%,
the lowest observed in any prior review, demonstrates several ﬁnd-
ings that may be pertinent to bending the mortality curve for
AAO. First, we believe extra-anatomic bypass with axillobifemoral
bypass offers a rapid revascularization strategy with less physiologic
strain on the critically ill patient with AAO and with acceptable
patency. Our review also demonstrates that the large majority of
AAOs are now due to in-situ aortic thrombosis rather than embo-
lism more commonly seen in prior decades. This change in the
epidemiology of the disease has implications for potential
improved survival of the AAO patient. Patients with progressive
aortoiliac disease with subsequent acute thrombosis may have
the beneﬁt of developing collaterals which may limit the severity
of tissue ischemia and ultimately affect outcome. In addition, in
the past, embolism may have been associated with acute myocar-
dial infarction, perhaps making recovery more difﬁcult for patients
studied in earlier series.
We do seek to identify patients presenting in severe extremis,
those with prohibitive comorbidities and end-stage malignancies,
as candidates for comfort care measures rather than attempted
revascularization. Early involvement of our colleagues from the
palliative care service can be very helpful in such cases.
We practice surveillance imaging after revascularization. Virtu-
ally all patients with bypass grafts placed for any indication are
examined with duplex ultrasound routinely prior to leaving the
hospital. We have not observed clinically detectable clot progres-
sion postoperatively. Following revascularization for acute aortic
occlusion, our patients are generally continued on anticoagulation
unless there is a contraindication to do so.
Again, we would like to thank Dr Morasch for his comments
and the Western Vascular Surgery for the opportunity to present
our work.
